Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Ono Files Opdivo for 1st-Line Treatment for Unresectable Advanced/Recurrent Gastric Cancer
Ono Pharmaceutical said on May 14 that it has submitted an application for its PD-1 inhibitor Opdivo (nivolumab) to expand its use for the treatment of previously untreated, unresectable, advanced, or recurrent gastric cancer.If approved, the drug will offer a…
To read the full story
Related Article
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





